Skip to main content

Psychiatric Drug Discovery

In Order to Read Online or Download Psychiatric Drug Discovery Full eBooks in PDF, EPUB, Tuebl and Mobi you need to create a Free account. Get any books you like and read everywhere you want. Fast Download Speed ~ Commercial & Ad Free. We cannot guarantee that every book is in the library!

Psychiatric Drug Discovery and Development

Psychiatric Drug Discovery and Development Book
Author : Strategic Research Institute
Publisher : Unknown
Release : 2003
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Psychiatric Drug Discovery and Development book written by Strategic Research Institute, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Drug Discovery for Psychiatric Disorders

Drug Discovery for Psychiatric Disorders Book
Author : Zoran Rankovic,Richard Hargreaves,Matilda Bingham
Publisher : Royal Society of Chemistry
Release : 2012-10-08
ISBN : 1849734941
Language : En, Es, Fr & De

GET BOOK

Book Description :

The discovery and development of effective medicines for the treatment of psychiatric disorders such as schizophrenia and depression has been heralded as one of the great medical achievements of the past century. Indeed, the profound impact of these medicines on our understanding of the pathophysiology underlying these diseases, the treatment of psychiatric patients and even our social perception of mental illnesses cannot be underestimated. However, there is still an urgent medical need for even more effective, safe and well-tolerated treatments. For example, currently available treatments for schizophrenia address mainly the positive symptoms and largely neglect the negative symptoms and cognitive disfunction which greatly impact overall morbidity. Similarly, whilst the current first line antidepressants show significantly improved side effect profiles compared to the first generation therapies, there still up to 40% of patients who are treatment resistant, and even in the patient population which responds well, the onset of action is slow at typically 2-3 weeks. The aim of this book is to provide the first point of call for those involved or just interested in this rapidly expanding and increasingly fragmented field of research and drug discovery. The editors will combine their wide ranging experience and extensive network of contacts with leading scientists and opinion leaders in this field to provide an authoritative reference text covering the evolution, major advances, challenges and future directions in drug discovery and medicinal chemistry for major psychiatric disorders, such as schizophrenia, depression, anxiety, ADHD, bipolar disorder, addiction and autism.

Animal and Translational Models for CNS Drug Discovery Psychiatric Disorders

Animal and Translational Models for CNS Drug Discovery  Psychiatric Disorders Book
Author : Robert A. McArthur,Franco Borsini
Publisher : Academic Press
Release : 2008-11-17
ISBN : 008092039X
Language : En, Es, Fr & De

GET BOOK

Book Description :

Psychiatric Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for psychiatric disorders such as anxiety, obsessive-compulsive disorder, depression, schizophrenia, bipolar disorder, ADHD, and autistic spectrum disorder. Psychiatric Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the first volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, and is also available for purchase individually. Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process Critical evaluation of animal and translational models improving transition from drug discovery and clinical development Emphasizes what results mean to the overall drug discovery process Explores issues in clinical trial design and conductance in each therapeutic area Psychiatric Disorders is available for purchase individually.

Modern CNS Drug Discovery

Modern CNS Drug Discovery Book
Author : Rudy Schreiber
Publisher : Springer Nature
Release : 2021-06-17
ISBN : 3030623513
Language : En, Es, Fr & De

GET BOOK

Book Description :

This textbook provides a comprehensive overview of the currently used concepts, approaches and technologies in the discovery and development of new treatments for the full spectrum of disorders of the central nervous system. It guides the reader through all essential steps, from finding an innovative idea, to the registration of a new drug. Divided into four sections, the book starts by presenting a broad perspective on current approaches in central nervous system (CNS) drug discovery. The second section addresses the generation of ideas for the identification of targets and novel treatment strategies; covers core functions in early discovery, and provides an example of a novel treatment paradigm: brain stimulation. The third section highlights strategies and technologies in translational CNS drug discovery. In an effort to bridge the gap between discovery and clinical development, it also covers brain imaging, EEG and cognitive testing approaches. The fourth section extensively discusses the clinical phase of drug development, covering the basics of early clinical testing for psychopharmacological drugs. The book’s final chapter addresses the registration for newly developed drugs. Written by experts from academia and industry, the book covers important basics and best practices, as well as recent developments in drug discovery. Offering in-depth insights into the world of drug development, it represents essential reading for early researchers who want to prepare for a career in drug discovery in academia or industry.

Polypharmacology in Drug Discovery

Polypharmacology in Drug Discovery Book
Author : Jens-Uwe Peters
Publisher : John Wiley & Sons
Release : 2012-01-20
ISBN : 1118098137
Language : En, Es, Fr & De

GET BOOK

Book Description :

An essential outline of the main facets of polypharmacology indrug discovery research Extending drug discovery opportunities beyond the "one drug, onetarget" philosophy, a polypharmacological approach to the treatmentof complex diseases is emerging as a hot topic in both industry andacademic research. Polypharmacology in Drug Discovery presents anoverview of the various facets of polypharmacology and how it canbe applied as an innovative concept for developing medicines fortreating bacterial infections, epilepsy, cancer, psychiatricdisorders, and more. Filled with a collection of instructive casestudies that reinforce the material and illuminate the subject,this practical guide: Covers the two-sided nature of polypharmacology—itscontribution to adverse drug reactions and its benefit in certaintherapeutic drug classes Addresses the important topic of polypharmacology in drugdiscovery, a subject that has not been thoroughly covered outsideof scattered journal articles Overviews state-of-the-art approaches and developments to helpreaders understand concepts and issues related topolypharmacology Fosters interdisciplinary drug discovery research by embracingcomputational, synthetic, in vitro and in vivo pharmacological andclinical aspects of polypharmacology A clear road map for helping readers successfully navigatearound the problems involved with promiscuous ligands and targets,Polypharmacology in Drug Discovery provides real examples, in-depthexplanations and discussions, and detailed reviews and opinions tospark inspiration for new drug discovery projects.

Drug Discovery for Schizophrenia

Drug Discovery for Schizophrenia Book
Author : Tatiana V. Lipina,John C. Roder
Publisher : Royal Society of Chemistry
Release : 2015-05-13
ISBN : 1782620265
Language : En, Es, Fr & De

GET BOOK

Book Description :

Since the pioneering pharmacotherapy for treatment of schizophrenia in the 1950s by antipsychotics, only a few major innovations have been made, pointing to a general stagnation in the field of pharmacology of schizophrenia. Drug Discovery for Schizophrenia covers new insights in the field of schizophrenia with an aim to advance the understanding of scientists and clinicians in this area and to fuel drug discovery. The book outlines a change in the way schizophrenia is treated by moving away from focusing only on treating symptoms in patients. Innovative drugs emerge from deeper comprehension of the pathological processes that emerge earlier in life, hence, providing strategies for preventative therapy to alter the course of this mental disorder. Amongst other current topics, the book covers new findings in genetics and epigenetics, progress in animal models for schizophrenia and the usage of induced pluripotent stem cells. The combination of these important areas benefit psychiatric neuroscience, filling the gaps in the knowledge of neurobiology of schizophrenia and providing novel perspectives for future drug development.

Animal and Translational Models for CNS Drug Discovery Reward Deficit Disorders

Animal and Translational Models for CNS Drug Discovery  Reward Deficit Disorders Book
Author : Robert A. McArthur,Franco Borsini
Publisher : Academic Press
Release : 2009-02-24
ISBN : 0080920403
Language : En, Es, Fr & De

GET BOOK

Book Description :

Reward Deficit Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for reward deficit disorders such as alcohol dependence, nicotine dependence, heroin and cocaine addiction, obesity, and gambling and impulse control disorders. Reward Deficit Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. Reward Deficit Disorders also has a section dedicated to the specifics of the regulatory aspects to abuse liability testing. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the third volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually. Provides clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process Critical evaluation of animal and translational models improving transition from drug discovery and clinical development Emphasizes what results mean to the overall drug discovery process Explores issues in clinical trial design and conductance in each therapeutic area Neurological Disorders is available for purchase individually.

Drug Discovery for Nervous System Diseases

Drug Discovery for Nervous System Diseases Book
Author : Franz Hefti
Publisher : Wiley-Liss
Release : 2005
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

The book focuses on drug discovery for psychiatric and neurological diseases, which is in a phase of explosive growth. Chapters are divided into two major sections. The first section presents fundamentals of drug discovery, highlighting the modern techniques and approaches of drug discovery in biotech and pharmaceutical companies.

Neurological Psychiatric Disorders Neurogenomics

Neurological   Psychiatric Disorders  Neurogenomics Book
Author : Stan M. Goldin,Timothy Tankosic,Susan C. DiClemente,Laura Carter
Publisher : Unknown
Release : 1997-01-01
ISBN : 9781579360917
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Neurological Psychiatric Disorders Neurogenomics book written by Stan M. Goldin,Timothy Tankosic,Susan C. DiClemente,Laura Carter, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Essential CNS Drug Development

Essential CNS Drug Development Book
Author : Amir Kalali,Sheldon Preskorn,Joseph Kwentus,Stephen M. Stahl
Publisher : Cambridge University Press
Release : 2012-06-07
ISBN : 1139576526
Language : En, Es, Fr & De

GET BOOK

Book Description :

Central Nervous System disorders have an enormous impact on individuals and on society as a whole. The development of better treatments is crucial and is a major focus of pharmaceutical and biotechnology companies. This book explains the complicated process of CNS drug development in a way that is engaging for any interested professional or student. Chapters cover each stage of drug development, from pre-clinical research through all phases of clinical trials, to reporting to the regulatory authorities. Other key issues covered include strategic considerations, regulatory constraints, dissemination of results and ethical considerations. The user-friendly format and style enable readers to find important information quickly and easily. Written and edited by experts from different sectors actively engaged in CNS drug development, this is a unique resource for drug developers, investigators, academics and clinicians.

Animal and Translational Models for CNS Drug Discovery Neurological Disorders

Animal and Translational Models for CNS Drug Discovery  Neurological Disorders Book
Author : Robert A. McArthur,Franco Borsini
Publisher : Academic Press
Release : 2008-11-18
ISBN : 9780080920382
Language : En, Es, Fr & De

GET BOOK

Book Description :

Neurological Disorders is written for researchers in both academia and the pharmaceutical industry who use animal models in research and development of drugs for neurological disorders such as neurofibromatosis, Alzheimer’s disease, Parkinson’s disease, Huntington disease, ALS, and the epilepsies. Neurological Disorders has introductory chapters expressing the view of the role and relevance of animal models for drug discovery and development for the treatment of psychiatric disorders from the perspective of (a) academic basic neuroscientific research, (b) applied pharmaceutical drug discovery and development, and (c) issues of clinical trial design and regulatory agencies limitations. Each volume examines the rationale, use, robustness and limitations of animal models in each therapeutic area covered and discuss the use of animal models for target identification and validation. The clinical relevance of animal models is discussed in terms of major limitations in cross-species comparisons, clinical trial design of drug candidates, and how clinical trial endpoints could be improved. The aim of this series of volumes on Animal and Translational Models for CNS Drug Discovery is to identify and provide common endpoints between species that can serve to inform both the clinic and the bench with the information needed to accelerate clinically-effective CNS drug discovery. This is the second volume in the three volume-set, Animal and Translational Models for CNS Drug Discovery 978-0-12-373861-5, which is also available for purchase individually. Clinical, academic, government and industry perspectives fostering integrated communication between principle participants at all stages of the drug discovery process Critical evaluation of animal and translational models improving transition from drug discovery and clinical development Emphasis on what results mean to the overall drug discovery process Exploration of issues in clinical trial design and conductance in each therapeutic area

Drug Discovery for Psychiatric Disorders

Drug Discovery for Psychiatric Disorders Book
Author : Zoran Rankovic,Richard Hargreaves,Matilda Bingham
Publisher : Royal Society of Chemistry
Release : 2012
ISBN : 1849733651
Language : En, Es, Fr & De

GET BOOK

Book Description :

This is a wide scope and in-depth coverage of the state of the art and future directions in drug discovery for major psychiatric disorders.

Neurological and Psychiatric Disorders Neurogenomics

Neurological and Psychiatric Disorders  Neurogenomics Book
Author : Stan M. Goldin,Timothy Tankosic
Publisher : Unknown
Release : 1997-01-01
ISBN : 9781579360924
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Neurological and Psychiatric Disorders Neurogenomics book written by Stan M. Goldin,Timothy Tankosic, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Neurological and Psychiatric Disorders Neurogenomics

Neurological and Psychiatric Disorders  Neurogenomics Book
Author : Stan M. Goldin,Timothy Tankosic
Publisher : International Business Communications
Release : 1997-01-01
ISBN : 9781579360948
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Neurological and Psychiatric Disorders Neurogenomics book written by Stan M. Goldin,Timothy Tankosic, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Psychiatric Genomics

Psychiatric Genomics Book
Author : Evangelia Eirini Tsermpini,Martin Alda,George P. Patrinos
Publisher : Academic Press
Release : 2020-12-15
ISBN : 9780128196021
Language : En, Es, Fr & De

GET BOOK

Book Description :

Psychiatric Genomics presents and synthesizes available knowledge in the field of psychiatric genomics, offering methodologies to advance new research and aid clinical translation. After providing an introduction to genomics and psychiatry, international experts discuss the genomic basis of schizophrenia, bipolar disorder, depression, personality disorders, anxiety disorders, addictions, eating disorders, and sleep disorders, among other disorders. In addition, recommendations for next steps in clinical implementation and drug discovery are discussed in-depth, with chapters dedicated to pharmacogenomics and antipsychotics, antidepressants and mood stabilizers, adverse drug reactions, implementation of pharmacogenomics in psychiatric clinics, and ethical issues. Finally, methods sections provide a solid grounding in research approaches and computational analytics, from using animal models in psychiatric genomics and accessing biobanks, to employing computational analysis, genome-wide association studies (GWAS), brain pathophysiology, and endophenotypes in psychiatric research. Thoroughly examines the genetic mechanisms underlying a broad range of psychiatric disorders Offers genomic methodologies and analytical approaches supporting new research and clinical translation, including personalized diagnosis and treatment models Features chapter contributions from international leaders in the field

Drug Discovery for the Treatment of Addiction

Drug Discovery for the Treatment of Addiction Book
Author : Brian S. Fulton
Publisher : John Wiley & Sons
Release : 2014-08-06
ISBN : 1118889576
Language : En, Es, Fr & De

GET BOOK

Book Description :

With addiction a key target for drug discovery efforts, this bookfills an important and timely need for medicinal chemists who needto understand complex neuroscience issues. The author illustratesmedicinal chemistry's prominent role in treating addiction andcovers specific drugs of abuse including narcotics, stimulants,depressants, nicotine, and marijuana. • Interprets complex neuro- biological andpharmacological information, like the drug-reward system, formedicinal chemists • Emphasizes neurotransmitters and neurochemicalmechanisms of addictive drugs • Pulls together information on the many potential drugtargets for treating addiction • Stresses unique medicinal chemistry problems whendescribing pharmacology testing methods and drug development

Preclinical Telemetric EEG Recordings and Behavioral Measurements to Investigate Efficacy and Tolerability in Psychiatric Drug Discovery

Preclinical Telemetric EEG Recordings and Behavioral Measurements to Investigate Efficacy and Tolerability in Psychiatric Drug Discovery Book
Author : Henrike Raith
Publisher : Unknown
Release : 2020
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

Download Preclinical Telemetric EEG Recordings and Behavioral Measurements to Investigate Efficacy and Tolerability in Psychiatric Drug Discovery book written by Henrike Raith, available in PDF, EPUB, and Kindle, or read full book online anywhere and anytime. Compatible with any devices.

Clinical Pharmacology in Psychiatry

Clinical Pharmacology in Psychiatry Book
Author : Lars F. Gram,Luc P. Balant,Herbert Y. Meltzer,Svein G. Dahl
Publisher : Springer Science & Business Media
Release : 2013-03-07
ISBN : 3642780105
Language : En, Es, Fr & De

GET BOOK

Book Description :

This book contains the papers from invited lecturers as well as selected contributions presented at the 6th International Meeting on Clinical Pharmacology in Psychiatry (I.M.C.P.P.) held in Geneva, Switzerland, 5-7 June 1991. At this meeting the basic theme of the previous meetings in this series (Chicago 1979, Troms0 1980, Odense 1982, Bethesda 1985, Troms0 1988) was continued, namely, to bridge the gap between experimental development and clinical reality in psychopharmacology. After more than 25 years of intensive research in biological psychiatry, basic understanding of the biological mechanisms underlying major psychiatric diseases has advanced significantly but is still far from complete. Likewise, the hypotheses underlying the development of new psychotropics have been refined and produced a wide spectrum of novel, yet designed compounds. The crucial condition for all progress in this field is reliable, informative clinical testing of new compounds. It is our hope that this book, as a continuation of the earlier publications in this series, provides further evidence of the ongoing interaction between preclinical and clinical scientists, who only together can assure progress in this exciting area of research and clinical practice.

Contributions to the Development and Validation of FMRI based Biomarkers for Drug Discovery in Social Anxiety Disorder

Contributions to the Development and Validation of FMRI based Biomarkers for Drug Discovery in Social Anxiety Disorder Book
Author : Héctor Ortiz València
Publisher : Unknown
Release : 2017
ISBN : 0987650XXX
Language : En, Es, Fr & De

GET BOOK

Book Description :

This document presents the theoretical background and experimental work made to develop and validate a set of experiments based on functional magnetic resonance imaging (fMRI). These experiments are aimed to demonstrate that fMRI can be a valuable tool to objectivize drug treatment response in Social Anxiety Disorder (SAD) patients. Functional MRI is a non-invasive imaging technique which provides localized indicators of brain activity. The analysis of fMRI data has recently facilitated neuroscience to make a leap forward in the understanding of the human brain. Psychiatric clinical research, however, hasn't fully embraced yet the potential of fMRI. In parallel, the societal costs of new psychiatric drug discovery are reaching unbearable limits. It has been hypothesized that the addition of fMRI in clinical trials of pharmacologic treatments of SAD can provide new biomarkers of treatment response which, in the future, shall reduce the temporal and economic burden of drug discovery. Five studies are presented in this dissertation in an evolving path towards the validation of the hypothesis. In study 1, a widely validated state-of-the-art emotional face processing paradigm was piloted in a non-clinical sample. Task related activations were in line with the findings previously reported in the literature. However, the results of experiment did not show a correlation with symptom severity. An additional exploratory psychophysiological interaction analysis revealed that the relationship between two emotion-processing areas had a significant correlation with SAD symptom severity. This emphasized the potential value of studies based on functional connectivity for our objectives. Study 2 explored the reproducibility of connectivity analysis of fMRI data. To do so, a brain network was selected and explored with Independent Component Analysis (ICA) on data collected from three categorically differentiated paradigms: A resting task, a moral dilemma task and in a cognitive-challenging Stroop task. The selected network was systematically identified in the three cases, exemplifying the robustness of the technique in three extreme cases. Study 3 explores the sensitivity of ICA by analyzing resting-state data acquired before and after an experimental induction of sad mood. Multiple regions reflected changes in their intranetwork connectivity after sad mood induction. Results were validated using a split-half re-analysis and confirmatory seed-based functional connectivity measurements. These results support the idea that spatial ICA of fMRI is not only reliable, but also a sensitive paradigm. Study 4 presents a novel SAD symptom-provoking paradigm that was validated on SAD patients and controls. The analysis of this pilot revealed a striking non-linear relationship between task activation and social anxiety scores. This non-linear relationship is compatible with some of the divergences found in literature regarding the alteration of emotional regulation brain areas in SAD. Study 5 presents the results of a small placebo-controlled clinical trial using a common treatment for SAD (paroxetine) in SAD patients. Subjects underwent the emotional face processing, the symptom-provoking and resting state tasks that were administered and analyzed following the experience obtained in studies 1 to 4. The selected fMRI paradigms and analysis methods showed significant sensitivity to the effects of paroxetine treatment on SAD. Treatment effects were identified in areas related to the processing of fear stress and anxiety, which are known to be altered in SAD. Remarkably, ICA revealed sensitivity to pharmacologically-induced clinical improvement in the same areas and direction than the symptom-provocation task. Along with the evidences reported in the literature review, the methods and results obtained throughout this dissertation provide a proof of concept on the usage of fMRI as a biomarker for SAD pharmacologic research.

Next Generation Antidepressants

Next Generation Antidepressants Book
Author : Chad E. Beyer,Stephen M. Stahl
Publisher : Cambridge University Press
Release : 2010-05-20
ISBN : 1139833030
Language : En, Es, Fr & De

GET BOOK

Book Description :

The World Health Organization defines depression as a primary contributor to the global burden of disease and predicts it will become the second leading cause of death by 2020. The need to develop effective therapies has never been so pressing. Current antidepressant drugs have several limitations. This 2010 book looks at the future of mood-disorder research, covering the identification of new therapeutic targets, establishing new preclinical models, new medicinal chemistry opportunities, and fostering greater understanding of genetic influences. These strategies are likely to help build a better picture of the disease process, and lead to new opportunities for patient stratification and treatment. The ultimate goal for this strand of research is to develop more personalized and effective treatments for this chronic and debilitating condition. This is essential reading for all those involved in psychopharmacologic drug development, and mental health clinicians seeking a preview of discoveries soon to influence their practice.